The RMGP Biopharma Fund targets
innovative early stage Biopharma
In partnership with FutuRx, an Israel-based, globally focused drug development platform,
founded by Orbimed, Johnson&Johnson and Takeda.
Early Stage
$90B
Early-stage exits in 2016,
60% of all biopharma exits.
An industry shift towards early-stage deals.
Driven by rising cost of drug development, big pharma is seeking innovative de-risked assets. As a result, recent years saw a steep increase in early-stage M&A and licensing deals.
BioPharma
9.4%
CAGR of
biopharmaceuticals market
BioPharma remains a strong investment opportunity.
Aging population, increase in healthcare spending,
and advancements in biology,
make biopharma an attractive sector.
Israel based
1300
Life science companies
Israel is an innovation Hub.
Israel is a leader in R&D spending and IP generation per capita, with a rapidly growing pipeline in a variety of healthcare segments.
Leading academic and research facilities
Drugs originating from Israel generate $41B in revenue
Global focus
